Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Off-Patent Study Requests Will Not Mirror Rate For Exclusivity

Executive Summary

FDA does not expect to issue written requests for studies of off-patent drugs at the same rate it has for patented drugs seeking pediatric exclusivity, Office of Counterterrorism & Pediatric Drug Development Director Dianne Murphy, MD, said

You may also be interested in...



FDA Reorganization Creates Prominent Roles For Mercy Hospital's Spielberg, CDER's Autor

Commissioner Hamburg places drug, biologics, devices and tobacco centers under Steven Spielberg's directorate; Deborah Autor becomes deputy commissioner for global regulatory operations and policy.

FDA Refers Wellbutrin SR, Zyban To NIH For Pediatric Studies

FDA is requesting that the National Institutes of Health conduct pediatric studies on GlaxoSmithKline's bupropion agents Wellbutrin SR and Zyban

FDA Refers Wellbutrin SR, Zyban To NIH For Pediatric Studies

FDA is requesting that the National Institutes of Health conduct pediatric studies on GlaxoSmithKline's bupropion agents Wellbutrin SR and Zyban

Related Content

UsernamePublicRestriction

Register

PS040055

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel